Details of the Drug

General Information of Drug (ID: DMZREFQ)

Drug Name

Eslicarbazepine

Synonyms

Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix

Indication

Disease Entry	ICD 11	Status	REF
Seizure disorder	8A6Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Neurology Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

254.28

Logarithm of the Partition Coefficient (xlogp)

1.4

Rotatable Bond Count (rotbonds)

0

Hydrogen Bond Donor Count (hbonddonor)

2

Hydrogen Bond Acceptor Count (hbondacc)

2

Chemical Identifiers

Formula: C15H14N2O2
IUPAC Name: (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
Canonical SMILES: C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
InChI: InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
InChIKey: BMPDWHIDQYTSHX-AWEZNQCLSA-N

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[2]
Voltage-gated sodium channel (Nav)	TTIG65Q	NOUNIPROTAC	Inhibitor	[3]
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)_{Main DME}	DEYGVN4	UD11_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Eslicarbazepine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Major	Increased metabolism of Eslicarbazepine caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[5]
Ripretinib	DM958QB	Moderate	Increased metabolism of Eslicarbazepine caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[5]
Avapritinib	DMK2GZX	Moderate	Increased metabolism of Eslicarbazepine caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[6]
Pemigatinib	DM819JF	Moderate	Increased metabolism of Eslicarbazepine caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[6]
Pralsetinib	DMWU0I2	Moderate	Increased metabolism of Eslicarbazepine caused by Pralsetinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[7]
Selpercatinib	DMZR15V	Moderate	Increased metabolism of Eslicarbazepine caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[6]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Eslicarbazepine caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[8]
Upadacitinib	DM32B5U	Moderate	Increased metabolism of Eslicarbazepine caused by Upadacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[9]
Larotrectinib	DM26CQR	Moderate	Increased metabolism of Eslicarbazepine caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[5]
-----------


⏷ Show the Full List of 9 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7350).
2	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
3	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4	Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metab Dispos. 2011 Sep;39(9):1486-94.
5	Cerner Multum, Inc. "Australian Product Information.".
6	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
7	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
8	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
9	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.